Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE

Immunotherapy Drug Shows Long-Lasting Response in Advanced Melanoma

By Drug Discovery Trends Editor | May 9, 2016

Dr. Antoni Ribas. Source: UCLAUCLA researchers have found that the immunotherapy drug pembrolizumab produces positive responses that are long-lasting and with fewer side effects than traditional treatments in people with advanced melanoma, the deadliest and most aggressive form skin cancer.

The study, published online in the journal JAMA Oncology, is a long-term follow-up of the phase 1 clinical trial that led to the approval of pembrolizumab by the Food and Drug Administration. The trial is the largest ever conducted in people with advanced melanoma, said Dr. Antoni Ribas, a professor of hematology and oncology, and director of the UCLA Jonsson Comprehensive Cancer Center Tumor Immunology Program.

“The early data from this research showed the unprecedented activity of pembrolizumab in people with advanced melanoma, and we can now report the full results of the study,” Ribas said.

Pembrolizumab (marketed as Keytruda) is a targeted therapy known as a checkpoint inhibitor. The drug is an antibody that blocks a protein called PD-1 that is expressed by immune cells. PD-1 puts the immune system’s brakes on, keeping T cells from recognizing and attacking cancer cells. Pembrolizumab releases the brakes from the body’s immune system which allows it to attack the cancer cells.

Ribas and his team analyzed data from 655 people who were treated with three dosing regimens of pembrolizumab. There were no differences among the dosing regimens, and overall the administration of the drug resulted in objective tumor regressions in 33 percent of patients. Among patients who were not previously treated for advanced melanoma, the objective tumor regression rate was 45 percent.

Toxicities were low, with 14 percent of patients having clinically significant toxicities, and only 4 percent had to stop treatment due to side effects. The great majority of responses were also highly durable, with 74 percent continuing beyond one year and up to over three years.

Ribas and colleagues also found that pembrolizumab was better tolerated and demonstrated superior progression-free survival compared to chemotherapy, and with no differences between pembrolizumab doses. The drug had fewer toxicities and significantly improved overall survival compared to the immunotherapy drug ipilimumab.


Filed Under: Drug Discovery

 

Related Articles Read More >

Chemical formula of psilocybin
Psychedelic pioneer Compass files for FDA approval as rivals close in
Insilico’s AI-designed TEAD inhibitor shrank tumors in 4 of 22 mesothelioma patients; randomized Phase 2a planned for 2027
If Trump gets Europe to pay more for drugs, more new medicines could follow — eventually
Antibody - visual concept of immune System - 3D illustration
Fresenius picks the biosimilars, WuXi Biologics builds them in a deal covering up to 37 candidates
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Drug Delivery Business News
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Pharmaceutical Processing World
  • R&D World
  • Subscribe to our E-Newsletter
  • About Us
  • Contact Us

Copyright © 2026 Arrowfly LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE